BERGEN, Norway, September 27, 2022 - BerGenBio ASA (OSE: BGBIO), a clinical
-stage biopharma-ceutical company developing novel, selective AXL kinase
inhibitors for severe unmet medical needs, and Oslo University Hospital
announced today that the first patient has been included in a study of
BerGenBio's oral, highly selective AXL inhibitor, bemcentinib, as part of the EU
-SolidAct trial in hospitalized COVID-19 patients.

The EU-SolidAct trial (European DisCoVeRy for Solidarity: An Adaptive Pandemic
and Emerging Infection Platform Trial) is part of EU-RESPONSE, a pan-European
research project designed to investigate treatment options for hospitalized
patients with COVID-19 and emerging infectious diseases.

Bemcentinib was selected by an international group of experts to be studied in
the EU-SolidAct platform in up to 500 hospitalized COVID-19 patients in a Phase
2b, multi-center, randomized, placebo-controlled trial.

Martin Olin, Chief Executive Officer of BerGenBio, commented: "COVID-19
infections and hospital admissions continues to evolve with new variants and the
expected fall/winter season impact. There is a need to identify new effective
therapies for hospitalized patients and bemcentinib represents a promising
treatment modality for this patient population through its unique mechanism of
action, blocking viral entry, stimulating the innate immune system and promoting
lung tissue repair. Importantly, bemcentinib enhances the Type I interferon
response, causing these cytokines to activate immune cells to fight the
infection regardless of spike protein or mutation. Based on the results of our
Phase 2a studies and learnings throughout the pandemic, we are eager to further
study the effectiveness of bemcentinib in COVID-19 and are delighted to now have
randomized the first patient in the EU-SolidAct platform."

The EU-SolidAct platform trial includes 68 clinical sites in 8 countries and is
sponsored by Oslo University Hospital, Norway, in collaboration with the
Institut National de la Santé Et de la Recherche Médicale (Inserm), France, and
the not-for-profit intergovernmental organization European Clinical Research
Infrastructure Network (ECRIN).

Professor Marius Trøseid, Oslo University Hospital, Chief Investigator of the EU
-SolidAct trial, commented: "As new subvariants continue to evolve, it is
critical to have greater treatment options in order to reduce hospital stays and
halt disease progression. We're pleased to be partnering with BerGenBio in the
initiation of this trial, as we look to enroll up to 500 hospitalized COVID-19
patients."

Contacts

For the EU-SolidAct:

Marius Trøseid, Chief Investigator of the EU-SolidAct trial, Senior Consultant
and Professor, Oslo University Hospital

+4792440240,marius.troseid@medisin.uio.no

For BerGenBio:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Investor Relations / Media Relations

Graham Morrell

Graham.morrell@bergenbio.com

+1 781 686 9600

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and COVID-19.

BerGenBio is based in Bergen, Norway, with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit www.bergenbio.com.

About Oslo University Hospital

Oslo University Hospital is a highly specialized hospital in charge of extensive
national, regional and local hospital assignments. As Scandinavia's largest
hospital, we carry out more than 1.2 million patient treatments each year. Oslo
University Hospital is responsible for approximately 50 percent of all medical
and health care research conducted at Norwegian hospitals. We have a leading
role in the development of research and innovation, as well as the development
of tomorrow's healthcare, precision medicine and treatment.

About Inserm

Founded in 1964, Inserm is a public science and technology institute. It is
dedicated to biomedical research and human health and is involved every step of
the way from the research laboratory to patient care. It is one of the most
prestigious institutions in the world that is committed to scientific challenges
and progress in these fields. Inserm brings together more than 15,000
researchers, engineers, technicians and administrative staff to improve the
health of all.www.inserm.fr/en/

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Suchrisks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.